Neurotrophic research
A mixture of neurotrophic peptide fragments with substantially more human clinical history than most compounds in this category.
Cerebrolysin is not a single peptide. It is a standardized preparation of low-molecular-weight peptides and amino acids derived from porcine brain tissue, developed decades ago and used clinically across parts of Europe and Asia. That history is what sets it apart here — most compounds on this page are supported by animal work and inference. Cerebrolysin has been given to a large number of human patients in controlled settings.
It behaves like a broad neurotrophic signal rather than a targeted drug. The peptide fragments appear to mimic the effects of the body's own nerve growth factors, supporting neuron survival, repair, and connection-building — which is why the studied indications are conditions where neurons are under stress or have been damaged.
Cerebrolysin's fragments exhibit neurotrophic activity resembling endogenous factors including BDNF, GDNF, NGF, and CNTF. Reported effects include enhanced neuronal survival under ischemic and excitotoxic stress, promotion of neurogenesis and synaptic density, modulation of amyloid processing, reduction of neuroinflammation, and improved mitochondrial function. It is administered parenterally, typically as a course of infusions or injections rather than continuously.
Cerebrolysin is used in courses rather than daily indefinitely, and the clinical literature evaluates outcomes over weeks to months. Anyone expecting an acute noticeable effect is likely to be disappointed — this is a slow, structural intervention studied against slow, structural problems.
Every page on this site includes this section. If a source only tells you what something does, you are reading marketing.
The clinical safety record across decades of use is reasonably favorable, with mild and transient adverse effects most commonly reported. Because it is porcine-derived, it is inappropriate for anyone with relevant allergy, and worth considering for those with religious dietary restrictions. Contraindicated in severe renal impairment and in epilepsy per its clinical labeling. Not FDA-approved. This is a compound that genuinely requires a provider.
Because it is a biological preparation rather than a synthesized single molecule, manufacturing consistency matters more here than almost anywhere else on this page. Provenance and cold chain are not optional details.
No. It is registered and used clinically in a number of countries in Europe and Asia, but not approved in the United States.
Yes — considerably more than most peptides discussed in this space, including randomized trials and meta-analyses in vascular dementia and stroke recovery. Effect sizes are moderate.
That use is not supported by the evidence. The trials studied people with existing cognitive deficits.
General education only goes so far. If you want help deciding whether this is relevant to your goals, history, and current labs, schedule a consultation with the Bearing team.
Request a Consultation